Haemonetics Financial Statements From 2010 to 2024

HAE Stock  USD 84.88  0.71  0.84%   
Haemonetics financial statements provide useful quarterly and yearly information to potential Haemonetics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Haemonetics financial statements helps investors assess Haemonetics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Haemonetics' valuation are summarized below:
Gross Profit
530.8 M
Profit Margin
0.0997
Market Capitalization
4.3 B
Enterprise Value Revenue
3.9401
Revenue
1.3 B
There are over one hundred nineteen available fundamental trends for Haemonetics, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Haemonetics' regular performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road.

Haemonetics Total Revenue

1.41 Billion

Check Haemonetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Haemonetics main balance sheet or income statement drivers, such as Interest Expense of 15.4 M, Total Revenue of 1.4 B or Gross Profit of 742.7 M, as well as many exotic indicators such as Price To Sales Ratio of 2.14, Dividend Yield of 0.0061 or PTB Ratio of 2.77. Haemonetics financial statements analysis is a perfect complement when working with Haemonetics Valuation or Volatility modules.
  
This module can also supplement Haemonetics' financial leverage analysis and stock options assessment as well as various Haemonetics Technical models . Check out the analysis of Haemonetics Correlation against competitors.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Haemonetics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding42.6 M46.3 M51.2 M
Slightly volatile
Total Assets2.3 B2.2 B1.5 B
Slightly volatile
Short and Long Term Debt Total924.8 M880.8 M475.7 M
Slightly volatile
Other Current Liabilities176.2 M167.8 M114.7 M
Slightly volatile
Total Current Liabilities156.2 M289.6 M229.9 M
Slightly volatile
Total Stockholder Equity519.7 M940.7 M699.1 M
Pretty Stable
Property Plant And Equipment Net179.1 M357.5 M264.9 M
Slightly volatile
Retained Earnings278.3 M291.1 M267 M
Slightly volatile
Accounts Payable77.2 M73.5 M51.4 M
Slightly volatile
Cash343.5 M327.1 M194.2 M
Slightly volatile
Non Current Assets Total1.4 B1.3 B860 M
Slightly volatile
Non Currrent Assets Other99.5 M123 M177.4 M
Slightly volatile
Cash And Short Term Investments343.5 M327.1 M194.2 M
Slightly volatile
Net Receivables117.3 M206 M150 M
Slightly volatile
Liabilities And Stockholders Equity2.3 B2.2 B1.5 B
Slightly volatile
Non Current Liabilities TotalB994.8 M498.7 M
Slightly volatile
Inventory313.2 M298.3 M214.4 M
Slightly volatile
Other Current Assets35.8 M53.7 M42.3 M
Very volatile
Other Stockholder Equity718.1 M683.9 M484.4 M
Slightly volatile
Total Liabilities1.3 B1.3 B738.5 M
Slightly volatile
Property Plant And Equipment Gross1.1 B1.1 B463.9 M
Slightly volatile
Total Current Assets929.4 M885.2 M608.8 M
Slightly volatile
Short Term Debt12.9 M13.6 M51.5 M
Pretty Stable
Intangible Assets333 M317.1 M219 M
Slightly volatile
Common Stock Total Equity421 K579.6 K477.5 K
Slightly volatile
Common Stock414.5 K579.6 K479.1 K
Slightly volatile
Other Liabilities131.1 M124.9 M58.6 M
Slightly volatile
Other Assets71 M67.6 M30 M
Slightly volatile
Long Term Debt910.6 M867.2 M425.8 M
Slightly volatile
Good Will563 M536.2 M315.3 M
Slightly volatile
Property Plant Equipment213.6 M357.5 M273.5 M
Slightly volatile
Retained Earnings Total Equity230.9 M227.9 M280.8 M
Slightly volatile
Long Term Debt Total910.6 M867.2 M423.3 M
Slightly volatile
Capital Surpluse516.6 M683.9 M487 M
Slightly volatile
Deferred Long Term Liabilities26.4 M41.6 M25.4 M
Slightly volatile
Non Current Liabilities Other133.9 M127.5 M59.7 M
Slightly volatile
Deferred Long Term Asset Charges3.3 MM3.5 M
Slightly volatile
Short and Long Term Debt10.1 M10.6 M162.6 M
Slightly volatile
Cash And Equivalents214.1 M327.1 M182.8 M
Slightly volatile
Net Invested Capital698.8 M689.3 M911.4 M
Slightly volatile
Net Working Capital380.9 M595.6 M267.3 M
Slightly volatile
Capital Stock405.9 K453.6 K498.4 K
Slightly volatile
Capital Lease Obligations6.2 M6.5 M46.1 M
Slightly volatile

Haemonetics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue1.4 B1.3 B937.9 M
Slightly volatile
Gross Profit742.7 M707.4 M461.6 M
Slightly volatile
EBITDA301.1 M286.7 M171 M
Slightly volatile
Depreciation And Amortization112.7 M107.3 M84.3 M
Slightly volatile
Other Operating Expenses546.5 M527.9 M728.9 M
Very volatile
Cost Of Revenue318.9 M636.6 M458.3 M
Slightly volatile
Total Operating Expenses554.3 M527.9 M371.8 M
Slightly volatile
Research Development32.4 M57.7 M41.2 M
Pretty Stable
Selling General Administrative227.4 M424.9 M295.8 M
Slightly volatile
Non Recurring630.4 K663.5 K21.7 M
Very volatile
Interest Income13.3 M16.8 M11.6 M
Slightly volatile
Reconciled Depreciation77.9 M84 M91.4 M
Very volatile
Selling And Marketing Expenses5.1 M8.3 M4.8 M
Slightly volatile

Haemonetics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow196.7 M187.3 M83.7 M
Slightly volatile
Begin Period Cash Flow313.3 M298.4 M184.3 M
Slightly volatile
Depreciation112.7 M107.3 M85 M
Slightly volatile
Capital Expenditures133.1 M126.7 M83.1 M
Slightly volatile
Total Cash From Operating Activities329.7 M314 M166.9 M
Slightly volatile
End Period Cash Flow343.5 M327.1 M194.2 M
Slightly volatile
Change To Netincome40.4 M41.6 M38.7 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.144.26982.9497
Slightly volatile
Dividend Yield0.00610.00860.0024
Slightly volatile
PTB Ratio2.775.12953.9012
Slightly volatile
Days Sales Outstanding77.9761.064461.9837
Pretty Stable
Book Value Per Share7.3414.262713.8909
Pretty Stable
Free Cash Flow Yield0.03260.03770.0396
Slightly volatile
Invested Capital0.260.33720.6085
Slightly volatile
Operating Cash Flow Per Share4.394.17694.0308
Slightly volatile
Stock Based Compensation To Revenue0.00940.01440.0152
Slightly volatile
PB Ratio2.775.12953.9012
Slightly volatile
EV To Sales2.194.35113.2054
Slightly volatile
Free Cash Flow Per Share2.92.7592.3479
Slightly volatile
Inventory Turnover2.973.05982.5389
Pretty Stable
Days Of Inventory On Hand116119147
Very volatile
Payables Turnover8.118.90289.7939
Slightly volatile
Sales General And Administrative To Revenue0.250.30360.3109
Slightly volatile
Research And Ddevelopement To Revenue0.05710.04340.0444
Pretty Stable
Cash Per Share1.983.41523.7815
Slightly volatile
POCF Ratio14.5717.515614.2594
Slightly volatile
Payout Ratio0.210.22710.0818
Slightly volatile
PFCF Ratio40.4126.516926.0781
Slightly volatile
Days Payables Outstanding43.1340.998238.2731
Slightly volatile
EV To Operating Cash Flow15.017.849215.47
Slightly volatile
EV To Free Cash Flow42.5827.021928.305
Slightly volatile
Intangibles To Total Assets0.160.29740.3097
Slightly volatile
Net Debt To EBITDA0.520.50561.3969
Pretty Stable
Current Ratio1.291.35482.5232
Pretty Stable
Tangible Book Value Per Share3.787.28744.3232
Slightly volatile
Receivables Turnover4.195.97735.922
Pretty Stable
Graham Number10.2616.649818.7874
Slightly volatile
Shareholders Equity Per Share7.3414.262713.8909
Pretty Stable
Debt To Equity0.260.33720.6085
Slightly volatile
Revenue Per Share8.7717.134418.1689
Slightly volatile
Interest Debt Per Share3.014.89459.2928
Slightly volatile
Debt To Assets0.140.2050.2971
Pretty Stable
Enterprise Value Over EBITDA13.7327.049217.8684
Slightly volatile
Short Term Coverage Ratios1.081.134310.5718
Slightly volatile
Operating Cycle238180212
Pretty Stable
Price Book Value Ratio2.775.12953.9012
Slightly volatile
Days Of Payables Outstanding43.1340.998238.2731
Slightly volatile
Dividend Payout Ratio0.210.22710.0818
Slightly volatile
Price To Operating Cash Flows Ratio14.5717.515614.2594
Slightly volatile
Price To Free Cash Flows Ratio40.4126.516926.0781
Slightly volatile
Ebt Per Ebit0.781.06191.1065
Slightly volatile
Effective Tax Rate0.320.23580.1489
Slightly volatile
Company Equity Multiplier1.31.64451.9251
Slightly volatile
Long Term Debt To Capitalization0.140.07320.3193
Pretty Stable
Total Debt To Capitalization0.180.25210.3592
Pretty Stable
Debt Equity Ratio0.260.33720.6085
Slightly volatile
Quick Ratio1.460.86141.5433
Pretty Stable
Net Income Per E B T0.420.76420.8342
Slightly volatile
Cash Ratio0.730.46830.8423
Slightly volatile
Cash Conversion Cycle142139170
Pretty Stable
Operating Cash Flow Sales Ratio0.130.24380.2033
Slightly volatile
Days Of Inventory Outstanding116119147
Very volatile
Days Of Sales Outstanding77.9761.064461.9837
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.340.66050.5522
Very volatile
Cash Flow Coverage Ratios0.830.86860.507
Very volatile
Price To Book Ratio2.775.12953.9012
Slightly volatile
Fixed Asset Turnover4.162.72143.2839
Slightly volatile
Price Cash Flow Ratio14.5717.515614.2594
Slightly volatile
Enterprise Value Multiple13.7327.049217.8684
Slightly volatile
Debt Ratio0.140.2050.2971
Pretty Stable
Cash Flow To Debt Ratio0.830.86860.507
Very volatile
Price Sales Ratio2.144.26982.9497
Slightly volatile
Asset Turnover0.90.73050.6895
Pretty Stable
Gross Profit Margin0.570.45570.4872
Slightly volatile
Price Fair Value2.775.12953.9012
Slightly volatile

Haemonetics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.7 B1.6 B1.9 B
Slightly volatile
Enterprise Value1.5 B1.4 B1.9 B
Slightly volatile

Haemonetics Fundamental Market Drivers

Forward Price Earnings19.6078
Cash And Short Term Investments284.5 M

Haemonetics Upcoming Events

8th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
9th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About Haemonetics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Haemonetics income statement, its balance sheet, and the statement of cash flows. Haemonetics investors use historical funamental indicators, such as Haemonetics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Haemonetics investors may use each financial statement separately, they are all related. The changes in Haemonetics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Haemonetics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Haemonetics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Haemonetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue34.7 M21.8 M
Total Revenue1.3 B1.4 B
Cost Of Revenue636.6 M318.9 M
Stock Based Compensation To Revenue 0.01  0.01 
Sales General And Administrative To Revenue 0.30  0.25 
Research And Ddevelopement To Revenue 0.04  0.06 
Capex To Revenue(0.08)(0.09)
Revenue Per Share 17.13  8.77 
Ebit Per Revenue 0.06  0.06 

Haemonetics Investors Sentiment

The influence of Haemonetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Haemonetics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Haemonetics' public news can be used to forecast risks associated with an investment in Haemonetics. The trend in average sentiment can be used to explain how an investor holding Haemonetics can time the market purely based on public headlines and social activities around Haemonetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Haemonetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Haemonetics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Haemonetics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Haemonetics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Haemonetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Haemonetics' short interest history, or implied volatility extrapolated from Haemonetics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:
Check out the analysis of Haemonetics Correlation against competitors.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.
Note that the Haemonetics information on this page should be used as a complementary analysis to other Haemonetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Complementary Tools for Haemonetics Stock analysis

When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Transaction History
View history of all your transactions and understand their impact on performance
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Commodity Directory
Find actively traded commodities issued by global exchanges
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stocks Directory
Find actively traded stocks across global markets
Is Haemonetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.05)
Earnings Share
2.46
Revenue Per Share
25.092
Quarterly Revenue Growth
0.101
Return On Assets
0.0612
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.